Syndax Pharmaceuticals, Inc. (SNDX) key performance indicators and operating metrics (11 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Nictimbo Collaboration Revenue (Net Commercial Profit Share) | 15.91M | FY2026-Q1 |
| Revuforge Net Revenue (Fourth Quarter) | 48.9M | FY2026-Q1 |
| Niktimvo Net Revenue (Incyte-Reported) | 55.1M | FY2026-Q1 |
| Revuforj Net Product Revenue | 48.9M | FY2026-Q1 |
| Research and Development Expenses | 58.85M | FY2026-Q1 |
| Selling, General and Administrative Expenses | 37.59M | FY2026-Q1 |
| Loss from Operations | -34.2M | FY2026-Q1 |
| Total Operating Expenses (Research and Development plus Selling, General and Administrative) | 99.07M | FY2026-Q1 |
| Basic Loss per Share Attributable to Common Stockholders | -0.48 USD_per_share | FY2026-Q1 |
| Cost of Product Sales | 2.63M | FY2026-Q1 |
| Loss Per Share Attributable to Common Stockholders | -0.70 USD_per_share | FY2025-Q3 |
Back to SNDX overview · SNDX earnings · SNDX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.